Atossa Lowers Expected Share Price for Planned IPO, Reports $223K in Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics lowered the expected share price for its planned initial public offering to between $4 and $6 per share, it disclosed in an amended Form S-1 filed on Monday with the US Securities and Exchange Commission.

The company also disclosed that it posted $223,097 in revenues for the second quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.